Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 7, 2014, Pages 4112-4119

  Yin, Bo ^a   Zeng, Yu ^a   Wang, Xiaosong ^b   Liu, Gang ^a   Zhang, Mo ^a   Song, Yongsheng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer testis (CT) gene; Clear cell renal cell carcinoma; Immunotherapy; Prognosis

Indexed keywords

MAGEA3 PROTEIN, HUMAN; MESSENGER RNA; TRANSCRIPTOME; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; BIOSYNTHESIS; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84906243553     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol 2012; 23 Suppl 8: viii35-40.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002; 11: 37-42.
4. Neumann E, Engelsberg A, Decker J, Störkel S, Jaeger E, Huber C, Seliger B. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 1998; 58: 4090-5.
5. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-17.
6. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003; 21: 3133-40.
7. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D. Eastern Cooperative Oncology Group/Intergroup trial. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21: 1214-22.
8. Nishizawa S, Hirohashi Y, Torigoe T, Takahashi A, Tamura Y, Mori T, Kanaseki T, Kamiguchi K, Asanuma H, Morita R, Sokolovskaya A, Matsuzaki J, Yamada R, Fujii R, Kampinga HH, Kondo T, Hasegawa T, Hara I, Sato N. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res 2012; 72: 2844-54.
9. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-25.
10. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 2006; 12: 5442-7.
11. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ, Ayyoub M. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 2007; 104: 8947-52.
12. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Gnjatic S. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A 2008; 105: 1650-5.
13. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-37.
14. Yamanaka K, Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S. Expression of MAGE genes in renal cell carcinoma. Int J Mol Med 1998; 2: 57-60.
15. Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM, Getzenberg RH. Cancer/testis antigens and urological malignancies. Nat Rev Urol 2012; 9: 386-96.
16. Yin B, Liu G, Wang XS, Zhang H, Song YS, Wu B. Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder. Urol Oncol 2012; 30: 886-92.
17. Li M, Yuan YH, Han Y, Liu YX, Yan L, Wang Y, Gu J. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res 2005; 11: 1809-14.
18. Sahin U, Türeci O, Chen YT, Seitz G, Villena-Heinsen C, Old LJ, Pfreundschuh M. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer 1998; 78: 387-9.
19. Scanlan MJ, Altorki NK, Gure AO, Williamson B, Jungbluth A, Chen YT, Old LJ. Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett 2000; 150: 155-64.
20. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A 2004; 101 Suppl 2: 14631-8.
21. Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A, Ritter G, Chen YT, Stockert E, Tsushima T, Kumon H, Old LJ, Nakayama E. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res 2001; 61: 4671-4.
22. Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, Kolb D, Geller MD, Hassoun H, Kewalramani T, Comenzo RL, Coplan K, Chen YT, Jungbluth AA. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 2003; 3: 9.
23. Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, Scanlan MJ, Ono T, Sakita I, Yasui M, Miyoshi Y, Tamaki Y, Matsuura N, Noguchi S, Old LJ, Nakayama E, Monden M. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004; 64: 2199-204.
24. Adams S, Greeder L, Reich E, Shao Y, Fosina D, Hanson N, Tassello J, Singh B, Spagnoli GC, Demaria S, Jungbluth AA. Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother 2011; 60: 999-1007.
25. Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, Spagnoli GC, Old LJ. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 2000; 85: 460-5.
26. Yawata T, Nakai E, Park KC, Chihara T, Kumazawa A, Toyonaga S, Masahira T, Nakabayashi H, Kaji T, Shimizu K. Enhanced expression of cancer testis antigen genes in glioma stem cells. Mol Carcinog 2010; 49: 532-44.
27. Gedye C, Quirk J, Browning J, Svobodová S, John T, Sluka P, Dunbar PR, Corbeil D, Cebon J, Davis ID. Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother 2009; 58: 1635-46.
28. Marturano J, Longhi R, Casorati G, Protti MP. MAGE-A3(161-175) contains an HLA-DRbeta4 restricted natural epitope poorly formed through indirect presentation by dendritic cells. Cancer Immunol Immunother 2008; 57: 207-15.
29. Ait-Tahar K, Liggins AP, Collins GP, Campbell A, Barnardo M, Lawrie C, Moir D, Hatton C, Banham AH, Pulford K. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. Br J Haematol 2009; 146: 396-407.
30. Errington JA, Conway RM, Walsh-Conway N, Browning J, Freyer C, Cebon J, Madigan MC. Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma. Br J Ophthalmol 2012; 96: 451-8.